A renal natriuretic peptide and the 'renal urodilatin system' were identified after the observation that immunoassayable ANP in urine may not be identical to the circulating cardiac hormone ANP, which is a peptide of 28 amino acids. Urodilatin (INN: Ularitide) is a natriuretic peptide isolated from human urine and belongs to the family of A-type natriuretic peptides. Urodilatin is differentially processed to a peptide of 32 amino acids from the same precursor as ANP. It is synthesized in kidney tubular cells and secreted luminally. After secretion from epithelial cells of the distal and / or connecting tubules, Urodilatin interacts downstream at distal segments of the 1 nephron with luminally located receptors whereby it regulates Na and water reabsorption. Thus, the physiological function of the renal 1 Urodilatin system can be described as a paracrine intrarenal regulator for Na and water homeostasis, considering Urodilatin as a real diuretic-natriuretic regulatory peptide. However, the regulation upon which the Urodilatin secretion depends is still not clear. Since Urodilatin has been discovered, a great number of pharmacological and clinical investigations have been carried out using Urodilatin as a drug for several indications. So far, clinical phase I and II studies for acute renal failure, congestive heart failure, and bronchial asthma have been performed.
Introduction and general considerations
granules of atrial myoendocrine cells [4, 11, 15] . The prohormone is processed into ANP-99-126 [16] while 1.1. Discovery of natriuretic peptides released into the circulation via exocytosis [15, 17, 18] . The other members of the natriuretic peptide family were Peptide hormones of the natriuretic peptide family have identified from the brain as brain natriuretic peptide (BNP been biochemically characterized since 1983 (see reviews or B-type natriuretic peptide) [13] , and CNP (C-type [1] [2] [3] [4] ). They were identified as regulatory diuretic-natnatriuretic peptide) [14] (Fig. 2) . The natriuretic peptides riuretic substances responsible for salt and water homeoshare common features and exhibit a specific tissue stasis [5, 6] and as hormones lowering blood pressure distribution of gene expression as well as functional and [7] [8] [9] [10] [11] . Later, a number of homologous peptides with pharmacological characteristics. manifold functional implications were described [12] [13] [14] . The natriuretic hormone cardiodilatin / atrial natriuretic 1.2. Localization und biochemistry of a-type natriuretic peptide (CDD/ANP) or A-type natriuretic peptide is peptides synthesized in the heart atrial myoendocrine cells as a precursor molecule of 126 amino acid residues (Fig. 1) ,
The different natriuretic peptides ANP, BNP, and CNP ANP-1-126 (CDD/ANP-1-126), and stored in specific have been detected in many organs showing expression by different techniques such as immunocytochemistry, detection of specific transcripts (mRNA determination or in situ hybridization), and by immunoassays of tissue extracts (for review, see [15] ). Many endocrine organs, the brain, and other systems show the widespread distribution of this responsible for this degradation is the metalloendoprotease peptide family. ANP (or A-type natriuretic peptide) [6] [7] [8] , E.C.3.4.24.11 [34, 36] . The localization of this protease in BNP [13] , and CNP [14] exhibit a similar, homologous the brush border of the kidney proximal tubule and in the primary structure of their processed functional form (Fig. lung shows the importance of these organs in the metabo-2). Less homology is seen between the precursors (Fig. 1) .
lism of natriuretic peptides. E.C.3.4.24.11 opens the loop In this review, special reference has to be made to the renal of CDD/ANP-99-126 between positions Cys-105 and Phelocalization of natriuretic peptides (see below), which was 106, inhibiting the receptor affinity and inactivating the shown in a series of immunocytochemical publications regulatory function of the peptide. [15] [16] [17] [18] [19] [20] [21] [22] [23] . In summary, all natriuretic peptides share common but also specific features, exhibiting tissue-specific distribution of gene expression which results in a diversity of functional and pharmacological characteristics.
2. Urodilatin, a renal natriuretic peptide
Receptors for and metabolism of natriuretic

Biochemistry and molecular biology of Urodilatin peptides
Urodilatin is a non-glycosylated peptide of 32 amino Natriuretic peptides mediate their activity by intracelluacid residues [12] considered as a naturally occurring lar generation of cyclic guanosine 39, 59-monophosphate human paracrine mediator [4, 15, 37, 38] . In 1988, (cGMP) [24, 25] . Type I membrane proteins have been Urodilatin was isolated from human urine [12] . The identified as receptors of natriuretic peptides which are peptide being synthesized in kidney tubules (Fig. 4a ) characterized by an intracellular domain of functional belongs to the family of A-type natriuretic peptides, guanylyl cyclase [26] [27] [28] [29] [30] . cDNA cloning resulted in the representing a differentially processed molecular form [4] discovery of three types of natriuretic peptide receptors (Fig. 6) . Urodilatin is N-terminally extended by 4 amino (NPR): NPR-A, B and C (see reviews, [28] [29] [30] ). Only acids, comparable to the circulating atrial natriuretic NPR-A and NPR-B exhibit the intracellular guanylyl peptide, ANP-99-126 [16] . Therefore, Urodilatin and cyclase catalytic domain, whereas the third cloned re-ANP-99-126 are derived from the same gene and a ceptor, NPR-C, contains no guanylyl cyclase domain. The common precursor peptide, ANP-1-126 (Fig. 6) . interaction with the NPR-A and G-protein-coupled reUrodilatin applied by intravenous injection, like other ceptors is depicted in Fig. 3 . natriuretic peptides, is inactivated by binding to the The inactivation of natriuretic peptides probably occurs natriuretic peptide clearance receptor (NPR-C) and by via two pathways, namely the binding to receptors and enzymatic degradation through the neutral endopeptidase enzymatic degradation [31] [32] [33] [34] [35] [36] [37] resulting in a half-life in NEP, E.C.3.4.24.11 [39] . In comparison to ANP-99-126, the range of less than a few minutes. In this respect, the Urodilatin is characterized by a higher stability against this physiological role of NPR-C has been described as a enzymatic degradation by neutral endoproteases [34] , clearance receptor. Besides binding of circulating natwhich explains why the renal effects are more effective riuretic peptides to NPR-C, enzymatic degradation takes when exogenous infusions of Urodilatin and ANP-99-126 place in lung, liver, and kidney [31] [32] [33] . The main enzyme are compared [40, 41] . Recently it was shown that natriuretic peptides may also phate (cGMP) [42, 43] (Fig. 3) . This receptor (NPR-A) is regulate renal electrogenic transport processes via cGMPlocated in kidney tubules (Fig. 4b) and also in the vascular dependent and cGMP-independent pathways based on the smooth muscle of the kidney [4, [44] [45] [46] [47] [48] [49] [50] as shown by presence of CNP-activated NPR-B which exists in at least different techniques of molecular biology, immunocytochtwo splice variants [51] . The significance of this 'CNP be explained by regulation of the Na transport by tion is correlated with Urodilatin excretion [59] . In some of influencing the potassium conductance [51] .
these experiments in which a natriuretic response is observed, circulating ANP-99-126 plasma levels are not 2.3. Systemic function of the intrarenal paracrine system changed at all [60] [61] [62] . Thus Urodilatin, the renal natriuretic peptide, is, by means of its paracrine interaction, an
1
The integration of the intrarenal paracrine system using essential physiological factor responsible for Na and Urodilatin as a diuretic regulator is considered to be of water regulation. great importance in systemic regulation, namely the con-1 trol of renal Na and water excretion (Fig. 7) . Thus, basically the homeostasis of body fluid and electrolytes 3. Pharmacology of Urodilatin depends on this paracrine Urodilatin system [52] [53] [54] [55] [56] . The relation of renal Urodilatin excretion and different experi-3.1. General pharmacological actions of Urodilatin ments in electrolyte homeostasis and imbalance have been investigated in animal studies and preclinical trials. LongSystemic administration of the peptide in normal rats 1 term Na diets in healthy volunteers revealed a significant [63] , dogs with cardiomyopathy [64] , and healthy volcorrelation between natriuresis and Urodilatin excretion:
unteers [65] shows the pharmacological effects on renal, 1 increased Na load was found by our group [52] to induce cardiovascular, or pulmonary parameters of Urodilatin.
1 an elevated Urodilatin excretion and an enhanced Na Enhanced diuresis, natriuresis, and a variable drop in blood excretion, as also shown by others [57] . Similarly, acute pressure have been observed. These effects are related to volume load by saline infusion [54] , balloon dilatation of the predominant vasodilation in renal, pulmonary, and the left atrium [53] , and water immersion [58] result in coronary arterial vessels and to electrolyte transport in 1 stimulated Urodilatin secretion and increased Na excrerenal tubules (Fig. 8 ). The lack of response or little sensitivity of vasorelaxation of other arterial vessels such peptide [69] . Urodilatin applied as a bolus in patients as mesenteric or peripheral arteries by Urodilatin results in suffering from congestive heart failure produces a modera redistribution of the blood stream in the body.
ate hypotension and a subsequent reflex tachycardia. In Bolus injections of Urodilatin in healthy volunteers are spite of these changes, Urodilatin is of benefit to the followed by a natriuresis and diuresis which are double patients as it significantly ameliorates cardiac index and that of exogenously applied ANP-99-126 in the same dose stroke volume [70] . ranges. In contrast, the hypotensive effect of Urodilatin is apparent only at higher doses than with ANP-99-126 3.2. Toxicology of Urodilatin [63] [64] [65] [66] [67] [68] .
Pulmonary parameters are distinctly influenced by Toxicology and pharmacological effects in animal Urodilatin, i.e. a bronchodilation (see below), as well as a models have so far shown no incompatibility reactions decrease of pulmonary arterial pressure and of pulmonary during or after local and systemic application of wedge pressure are found after bolus injection of the Urodilatin. When doses used in preclinical acute and long- term infusions were applied in amounts 10-100-fold 3.3. Impact of specific pharmacological actions of higher than those administered in clinical trials, these were Urodilatin tolerated and led to no clinical toxic effects. Urodilatinrelated histopathological alterations in different species
The Urodilatin system plays an important role in smooth were not observed (unpublished data). Daily intravenous muscle dilatation, electrolyte-body fluid homeostasis, and administration of Urodilatin to pregnant rats showed no immune defense. To further understand the multi-funcinfluence on organogenesis and no adverse effects on tional role of Urodilatin, in particular as a drug candidate maternal performance or survival, growth, and embryonic for potential clinical indications, the pharmacological development. No hints of mutagenic activity or chromoeffects of Urodilatin and other natriuretic peptides are somal aberrations were detected in any in vitro experisummarized in this following section (see Fig. 8 ). tracellular domain of the NPR-A (Fig. 3) . Further downcreases sympathetic nervous activity by stimulation of stream, the generation of cGMP then leads to the activation vagal afferences [73] , and thereby contributing to the of cGMP-dependent protein kinase and subsequently to a diminution of the smooth muscular tonus of the vascular 21 decrease of intracellular Ca concentration thereby relaxsystem. 1 ing smooth muscle. This effect is in concert with several Na homeostasis is triggered by several mechanisms GPCRs (G protein-coupled receptors) such as b -receptors such as the antagonism of renin and the inhibition of 2 (see Fig. 3 ). The resulting vasorelaxant activity of angiotensin. ANP-99-126 and BNP decrease renin secreUrodilatin and synthetic human ANP-99-126 in physiologtion from the macula densa, directly inhibit aldosterone ical and pharmacological concentrations was determined secretion from the zona glomerulosa, and attenuate the on precontracted vascular strips and demonstrated an stimulatory effect of angiotensin II on aldosterone release equipotent dose-dependent relaxation [36] . [73, 74] . The interaction with aldosterone was seen in The airway-relaxing effects of Urodilatin were shown in studies with healthy volunteers. These demonstrated that vitro [71] , using tracheal muscle strips and in in vivo aldosterone levels decrease significantly in a dose-depenexperiments in rodents [72] . Catecholamine inhibition is dent manner following Urodilatin infusion [75, 76] . detected in studies demonstrating that ANP-99-126 de-
The diuretic effect of Urodilatin is certainly the primary physiological role of this regulatory peptide. As shown in 5. Clinical implications of Urodilatin trials with healthy volunteers, Urodilatin induces a strong 1 diuresis and natriuresis under different Na diets [65] .
Heart failure Furthermore, Urodilatin administered in bolus injections in healthy volunteers results in a natriuresis and diuresis
Cardiovascular effects important in the treatment of which are stronger than those induced by ANP-99-126 heart failure, have been shown for Urodilatin. In this [69] .
respect, the increase of cardiac index and heart rate The impact of natriuretic peptides modulating the improduced by the peptide is of great importance [69] . As mune defense is derived from the observation that ANPUrodilatin also decreases mean pulmonary arterial pres-99-126 inhibits macrophage activity. This action is sugsure, pulmonary capillary wedge pressure (PCWP), and gested to be mediated by the NPR-A expressed in macrosystemic vascular resistance in healthy human volunteers, phages and the subsequent increase of intracellular cGMP the peptide was proposed as an effective drug candidate levels which in turn reduces e.g. the activation of NF-kB [69] . [77] .
In patients with congestive heart failure NYHA III-IV, intravenously administered Urodilatin increased cardiac index and decreased pulmonary artery pressure, pulmonary capillary wedge pressure, pulmonary and systemic vascular 4. Galenics of Urodilatin resistance [70, 78, 79] . In a randomized, double-blind, placebo-controlled study, infusion of Urodilatin (15 ng / Urodilatin-acetate as a basic peptide comprising 32 kg / min) for 10 hrs significantly decreased systolic blood amino acids, including its two L-cysteines with an inpressure and central venous pressure. Furthermore, urine 1 trapeptide disulfide bridge, is manufactured synthetically in flow as well as urinary Na excretion were significantly two fragments by the Merrifield solid phase method and increased. These effects are accompanied by an increase in then condensed and highly purified. The acetate serves as plasma and urinary cGMP levels. No neurohumoral activathe neutralizing and stabilizing counter ion and is introtion or adverse side effects were observed [78] . duced at the final purification stage. By definition of our
The beneficial effects of Urodilatin in patients suffering formulation, acetate is part of the Urodilatin-acetate molefrom cardiac failure have been confirmed by other natcule and is contained in the active ingredient preparation.
riuretic peptides. Infusion of ANP-99-126 or brain natThe finished product Urodilatin-acetate is supplied as riuretic peptide (BNP) in patients with congestive heart sterile lyophilisate in vials for injection purposes confailure improved left ventricular function by vasodilation taining Urodilatin-acetate corresponding to 1.0 mg of pure and noticeable natriuretic action [79] . Urodilatin. The formula which is used in clinical trials contains mannitol as the only other excipient. Urodilatin is 5.2. Urodilatin in renal insufficiency administered by intravenous infusion after being dissolved complication after major surgical interventions due to concentration of cyclic adenosine monophosphate (cAMP) hemodynamic, ischemic or vasoconstrictive mechanisms inducing a bronchodilation. [80] [81] [82] . The vasoconstrictive effect of cyclosporine A on A randomized, double-blind, placebo-controlled clinical arterial circulation [81] was suggested to be a particular phase II study with cross-over design, using intravenous reason for ARF in the post-operative phase after organ infusions of Urodilatin at various doses (Fig. 9) showed transplantation. Therefore, the predominant vasorelaxant beneficial effects in patients suffering from bronchial effect of natriuretic peptides on vascular smooth muscle in asthma [92] . Urodilatin increases forced expiratory volume the kidney was postulated to intervene with incipient renal in 1 s (FEV ), maximal vital capacity (VC ), peak 1 .0 max failure in major surgery. Experimental studies showed that expiratory flow (PEF), maximal expiratory flow at 75% natriuretic peptides such as Urodilatin may exert a benefi-(MEF ), at 50% (MEF ) and at 25% (MEF ) of forced 75 50 25 cial effect in ARF [83, 84] . vital capacity (FVC) at infusion doses of 10, 30 or 60 In the past, Urodilatin was used for prevention and ng / kg / min. Optimal effects were observed at Urodilatin therapy of acute renal failure following e.g. organ [85, 86] doses of 30 and 60 ng / kg / min. A further objective of this and bone marrow transplantation [87] in pilot studies. study was to show whether the bronchodilatory effects of Overall, Urodilatin significantly improved the deteriorated intravenously administered Urodilatin compared with renal function as demonstrated by the decrease in serum inhaled albuterol or whether a combination of the two creatine and blood urea nitrogen and the reduction of drugs can improve the efficacy of the treatment. Urodilatin hemodialysis / hemofiltration. monotherapy shows a bronchodilation which is comparable A pivotal phase II trial assessing the effects of to that induced by a standard dose of albuterol. Urodilatin Urodilatin in patients with oliguric ARF following cardiac infusion combined with albuterol inhalation results in a surgery, heart or liver transplantation [86] did not reveal a significantly stronger bronchodilatory effect compared to significant difference in patient outcome (avoidance of that obtained by monotherapy of either drug [91] (Fig. 9 ). hemodialysis) in the Urodilatin-treated groups versus
The pharmacological effects of Urodilatin, such as diplacebo. These results are in contrast not only with our uresis, drop in central venous pressure, and pulmonary previous results but also with a study which was performed resistance, are considered to be of additional benefit for by Allgren and coworkers [88] . In this trial, ANP adminispatients suffering from cor pulmonale. We conclude from tration revealed a significant improvement of dialysis-free this study [92] that the use of Urodilatin combined with a survival in a subgroup analysis in patients with oliguric b -agonist in the treatment of acute asthma exacerbation 2 acute tubular necrosis. The reason for the differences observed in these trials, is probably the difference in criteria for inclusion of patients. In the studies without successful treatment, the patient collective contained mostly multimorbid cases and patients with serious clinical conditions. These results with the different trials indicate that an earlier intervention at the onset of oliguria / anuria would have been more adequate to demonstrate the beneficial effect of Urodilatin. As the time interval of incipient oliguria / anuria was too long, the renal deterioration possibly due to peri-or post-operative renal hypoperfusion could already have entered into an irreversible tubular necrosis. These considerations favor an approach by prophylactic treatment with Urodilatin in risk patients for ARF. in vitro using tracheal muscle strips [89] . In vivo experiinhalation) and Urodilatin (infusion 30 ng / kg / min infused for 60 min) is ments in rodents confirmed these results [90] and later in compared to treatment with albuterol alone, Urodilatin alone, and control.
Urodilatin in bronchoconstriction and acute asthma
patients with mild asthma [91] . The bronchodilatory will result in a significant improvement in the outcome of 6.4. Erectile dysfunction these patients [92, 93] .
Urodilatin infusion may also result in an improvement The induction of penile erection depends on a complex of pulmonary function in patients with bronchial asthma system of signal transduction pathways resulting in cyclic and other obstructive pulmonary diseases when given nucleoside monophosphate changes of corpus cavernosus periodically. Urodilatin treatment can be of advantage for smooth muscle. In particular, cAMP and cGMP generated patients with cardiovascular risk and in patients when the by the corresponding adenylyl and guanylyl cycles as well intervention via the cAMP-mediated mechanism of bronas the modulation of the activity of the cyclic nucleoside chodilation is not effective, due to receptor desensitization monophosphate degrading phosphodiesterases play a pivotand downregulation. Then, the alternative cGMP-mediated al role in the modulation of the smooth muscle tonus of bronchodilatory mechanism induced by Urodilatin can be corpus cavernosus. Thus, the enzymes involved represent used for more beneficial treatment [93] .
important target molecules for the development of drugs for the treatment of erectile dysfunction [103] . Guanylyl cyclase B (NPR-B), a receptor for the C-type natriuretic 6. Further potential clinical applications of peptide (CNP) is expressed in human corpus cavernosus natriuretic peptides [104] . CNP induces an increase in intracellular cGMP levels as well as the relaxation of penile smooth muscle 6.1. Hepatorenal syndrome strips showing the role of CNP and its receptor in penile erection and its possible future use as a therapeutical The clinical course of patients with decompensated approach in erectile dysfunction. Laennec's cirrhosis is frequently complicated by progres-1 sive impairment of renal Na handling, leading to formation of ascites and peripheral edema [94] [95] [96] . Since the 7. Summary of the status quo of the clinical natriuretic peptides are shown to participate in the reguladevelopment of natriuretic peptides tion of volume homeostasis [97, 98] [65, 100] . Therefore, the therapeutreatment of acute heart failure in the USA. The peptide is tic effect of Urodilatin administered in patients suffering planned to be administered during the first 24 h of from hepatorenal syndrome combined with ascites was hospitalization for AHF to normalize hemodynamic disturassessed and Urodilatin was found to be effective in bances [106] . The therapeutic benefit of BNP has been 1 increasing Na and urine output in these patients [101] . substantiated in phase II and phase III trials in patients suffering from AHF [107] [108] [109] . The pharmacological 6.2. Immune defense concept for BNP is suggested to be an alternative to nitrates in the treatment of AHF. Food and Drug AdminisNatriuretic peptides have been shown to be involved in a tration approval is expected for the year 2001. number of further physiological and pharmacological mechanisms which may be of future clinical interest. The 7.3. ANP implication of ANP-99-126 and macrophage functions in the sense of suppression of macrophage activation by ANP (INN: Carperitide) is registered for the market in autoregulation is under discussion [77] . Thereby, the NPRJapan for the therapy of AHF. Studies in patients with A of macrophages inhibit by cGMP increase the activation AHF revealed beneficial hemodynamic effects such as of NF-kB and AP-1 which in turn reduces the TNF-a decrease in PCWP, systemic vascular resistance, and an transcription and release of TNF-a [101] .
increase in natriuresis and diuresis. Administration of ANP-99-126 in patients suffering from AHF results in a 6.3. Modulation and innate defense mechanisms significant improvement of left ventricular function by reduction of pre-and afterload [110] [111] [112] [113] . Recent results indicate that BNP exhibits an anti-
In conclusion, natriuretic peptides demonstrate a pharmicrobiotic effect on specific germs [102] , the significance macological profile which is desirable for the treatment of of which is still under investigation.
patients suffering from AHF. Clinical studies of ANP-99- 
